<DOC>
	<DOCNO>NCT02976779</DOCNO>
	<brief_summary>This single center , prospective , double-blind , placebo-controlled , randomize two part study ( part I part II ) ass safety topical cream ( 3 % CBD 3 % THC ) , apply twice daily ( bid ) , healthy subject , 6 treatment week additional 2 follow-up week .</brief_summary>
	<brief_title>A Phase I , Double Blind , Randomized , Placebo Controlled , Maximal Dose Study Determine Safety , Tolerability Topical Cream Containing MGC ( Medical Grade Cannabis ) Healthy Volunteers</brief_title>
	<detailed_description>The study divide 2 stage . Healthy subject consent participate study . Part I design evaluate single dose safety assessment single application MGC cream 26 healthy volunteer ( intact skin ) 24 consecutive hour admission condition clinical site . In stage , subject divide 3 application dos . The following procedure perform : - Time point 0- IV line , BP , Heart Rate , Blood test ( chemistry , blood count , Cannabinoids ) clinician evaluation cannabis related psychological aspect ( evaluation cannabis abuse screen test ) . - Time point 6 Hours- BP , Heart Rate Blood testing ( chemistry , blood count , Cannabinoids ) - Time point 12- BP , Heart Rate , Blood test ( chemistry , blood count , Cannabinoids ) - Time point 24- BP , Heart Rate , Blood test ( chemistry , blood count , Cannabinoids ) clinician evaluation cannabis related psychological aspect ( evaluation cannabis abuse screen test ) . Part II follow 24 hour ( part I ) design evaluate repeat application safety MGC cream healthy volunteer 6 week , clinic subject home . 20 healthy subject treat twice daily : - Maximal dose 30 mg CBD : 30 mg THC , 1:1 ratio - Placebo Control - 0 mg CBD : 0 mg THC , 1:1 ratio ( vehicle ) This stage initiate least 96 hour completion part I study ( washout period ) .The placebo apply one arm control second arm . Both , subject investigator blind product/placebo allocation . Application home perform twice day . Subjects ask attend clinic day 0 part II treatment , week 6 week daily application 2 week post application . In visit follow evaluation perform : BP , Heart Rate , Blood test ( chemistry , blood count , Cannabinoids ) clinician cannabis related psychological aspect ( evaluation cannabis abuse screen test ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test electrocardiogram ( ECGs ) . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator OWC Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects hemoglobin ( Hb ) value high ULN normal range always exclude enrollment . A female subject eligible participate nonchildbearing potential ( postmenopausal premenopausal female document tubal ligation hysterectomy ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol . Male subject female partner childbearing potential must agree use one contraception method list protocol . Agree participate interventional clinical trial study Agree follow study instruction meticulously A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Have evidence significant , uncontrolled hematological , endocrine , cerebrovascular , cardiovascular , coronary , pulmonary , gastrointestinal , neurological disease . ( Participants hypothyroidism adequate stable thyroid replacement exclude ) . History malignancy within 5 year Screening strong family history cancer ( e.g. , familial cancer disorder ) , exception squamous cell basal cell carcinoma skin definitively treat . A history drug alcohol abuse , history regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mililiter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Consumption : Barbiturates , Cocaine , Ethanol , SSRI 's , Protease inhibitor , Warfarin , Sildenafil , Theophilline , Tricyclic antidepressants A positive test human immunodeficiency virus ( HIV ) antibody . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives ( whichever longer ) . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator OWC Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator OWC Medical Monitor , contraindicate participation . Pregnant female determine positive urine human chorionic gonadotropin test screen prior dosing . Are pregnant nursing , child bear potential practicing effective mean birth control . Are able give adequate inform consent . Have current problem history substance abuse , opinion investigator , might interfere participation protocol . Have use marijuana within month start study . Fail initial urine drug screen blood test test illicit drug use within prior month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>